关于先锋

Company Profile

Pioneer Information

Notice Announcement

Industry News

Environmental information disclosure

03-10

2021

The Relationship between Various Entities in the Pharmaceutical Industry Chain - Production and MAH System

The Drug Marketing Authorization Holder (Marketing Authorization Holder, MAH) system is closely related to the production of drugs. In the MAH system, the holder refers to the company or drug research and development institution that has obtained the drug registration certificate. The MAH can be a domestic company or an overseas company. , the system separates the production license from the marketing license, and the holder can produce drugs by itself, or entrust domestic and foreign drug manufacturers to produce. However, in principle, blood products, narcotic drugs, psychotropic drugs, toxic drugs for medical use, and pharmaceutical precursor chemicals are not allowed to be commissioned for production.

09-24

2020

Cooperation in the field of big health

On Wednesday, September 23, 2020, cooperative customers in the field of general health visited Pioneer, accompanied by Chairman Chen Dong, Vice President of Sales He Chuanlan, Sales Director Gao Lixia, Marketing Director Li Xiaobao, etc. Customers have fully recognized Pioneer's product technology and quality standard system, as well as the after-sales system. In the later stage, we will explore new models together and strengthen cooperation.

09-08

2020

The board of directors of Pioneer Pharmaceutical visited multiple pharmaceutical companies and reached strategic cooperation

At the end of August 2020, Chairman Chen and General Manager Zheng Jian of Pioneer Pharmaceuticals visited pharmaceutical companies in Zhongshan, Zhuhai, Shenzhen, Chengdu, and other places. They had in-depth communication and exchange with leaders of various companies on matters such as company listing and generic drug research and development, and reached multiple strategic collaborations.

09-08

2020

The board of directors of Pioneer Pharmaceutical visited multiple pharmaceutical companies and reached strategic cooperation

The board of directors of Pioneer Pharmaceuticals visited a number of pharmaceutical companies and reached strategic cooperation At the end of August 2020, Chairman Chen and General Manager Zheng Jian of Pioneer Pharmaceuticals visited pharmaceutical companies in Zhongshan, Zhuhai, Shenzhen, Chengdu and other places, and had in-depth communication with the heads of various companies on matters such as company listing and generic drug research and development. , and reached a number of strategic cooperation.

09-02

2020

Good news! Schubert ® Fenofibrate capsule is launched

good news! Shubeite® Fenofibrate Capsules Launched Fenofibrate Capsules belong to the third generation of fibrate lipid-lowering drugs, and are mainly used clinically to treat elevated triglyceride (TG), elevated very low-density lipoprotein (VLD), low-density lipoprotein cholesterol (LDL- C) Dyslipidemia characterized by elevated and decreased high-density lipoprotein (HDL). By activating peroxisome proliferator-activated receptor α to play a protective role in blood vessels, it can significantly reduce the risk of microvascular complications in patients with hyperlipidemia, metabolic syndrome, and type 2 diabetes. Micronized technology, uniform release, regular absorption, greatly improved bioavailability and curative effect.

09-02

2020

Approved "Sodium Phosphate Creatine for Injection"

"Sodium creatine phosphate for injection" was approved" Creatine Phosphate Sodium for Injection is an injection declared by our company according to the 6 types of original chemical drugs. This product was established in 2010, and supplementary research was carried out in 2017. In 2019, we experienced on-site inspection. Under the leadership of Chairman Chen Zhenghao, The two major R&D centers of the company, Hefei and Shanghai, cooperated sincerely, and all links of R&D, production, quality, and procurement were united and united, and finally approved on March 24, 2020. This is another new milestone in the company's development history!

09-02

2020

Anhui University of Chinese Medicine • Anhui Pioneer Pharmaceutical Co., Ltd. Industry University Research Cooperation Symposium

Anhui University of Traditional Chinese Medicine Anhui Pioneer Pharmaceutical Co., Ltd. Industry-university-research cooperation symposium On the afternoon of August 26, 2020, at the invitation of the leaders of the School of Pharmacy, Anhui University of Traditional Chinese Medicine, Chairman Chen Zhenghao of Anhui Pioneer Pharmaceutical Co., Ltd. and a group of people visited the company's Friendship College - School of Pharmacy, Anhui University of Traditional Chinese Medicine. At Anhui University of Traditional Chinese Medicine, Chairman Chen Zhenghao and his team were warmly received by the Secretary of the School of Pharmacy Wu Dawu, Dean Gui Shuangying and other leaders, and conducted in-depth exchanges on cooperation in various aspects such as industry-university-research, co-construction of laboratories and practice bases.

09-01

2020

Warmly congratulate Pioneer Pharmaceuticals on being awarded the most valuable investment enterprise in China's pharmaceutical industry

The annual information conference, which enjoys the reputation of "Weather vane of the pharmaceutical industry", closely focuses on current affairs policies, research and development directions, marketing strategies, and investment, financing, M&A hotspots, and invites industry leaders and field experts to talk about their respective strengths, contend with a hundred schools of thought, and examine the industry trend and future from multiple perspectives.

< 1...6789 >